These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 23389496)
1. Impact of conditioning on outcome of hematopoietic stem cell transplantation for wiskott-Aldrich syndrome. Stepensky P; Krauss A; Goldstein G; Zaidman I; Elhasid R; Bielorai B; Somech R; Or R; Stein J; Revel-Vilk S; Weintraub M J Pediatr Hematol Oncol; 2013 Aug; 35(6):e234-8. PubMed ID: 23389496 [TBL] [Abstract][Full Text] [Related]
2. Allogeneic hemopoietic stem cell transplantation (HSCT) for Wiskott-Aldrich syndrome: a report of the Spanish Working Party for Blood and Marrow Transplantation in Children (GETMON). Muñoz A; Olivé T; Martinez A; Bureo E; Maldonado MS; Diaz de Heredia C; Sastre A; Gonzalez-Vicent M; Pediatr Hematol Oncol; 2007 Sep; 24(6):393-402. PubMed ID: 17710656 [TBL] [Abstract][Full Text] [Related]
3. Allogeneic stem cell transplantation using myeloablative and reduced-intensity conditioning in patients with major histocompatibility complex class II deficiency. Al-Mousa H; Al-Shammari Z; Al-Ghonaium A; Al-Dhekri H; Al-Muhsen S; Al-Saud B; Arnaout R; Al-Seraihy A; Al-Jefri A; Al-Ahmari A; Ayas M; El-Solh H Biol Blood Marrow Transplant; 2010 Jun; 16(6):818-23. PubMed ID: 20079864 [TBL] [Abstract][Full Text] [Related]
4. Outcome in patients with Wiskott-Aldrich syndrome following stem cell transplantation: an analysis of 57 patients in Japan. Kobayashi R; Ariga T; Nonoyama S; Kanegane H; Tsuchiya S; Morio T; Yabe H; Nagatoshi Y; Kawa K; Tabuchi K; Tsuchida M; Miyawaki T; Kato S Br J Haematol; 2006 Nov; 135(3):362-6. PubMed ID: 17032176 [TBL] [Abstract][Full Text] [Related]
5. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia. Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465 [TBL] [Abstract][Full Text] [Related]
6. Comparison of total body irradiation vs busulfan in combination with cyclophosphamide as conditioning for unrelated stem cell transplantation in CML patients. Kröger N; Zabelina T; Krüger W; Renges H; Stute N; Kabisch H; Jaburg N; Löliger C; Krüll A; Zander AR Bone Marrow Transplant; 2001 Feb; 27(4):349-54. PubMed ID: 11313663 [TBL] [Abstract][Full Text] [Related]
7. Reduced intensity conditioning using intravenous busulfan, fludarabine and rabbit ATG for children with nonmalignant disorders and CML. Horn B; Baxter-Lowe LA; Englert L; McMillan A; Quinn M; Desantes K; Cowan M Bone Marrow Transplant; 2006 Feb; 37(3):263-9. PubMed ID: 16327813 [TBL] [Abstract][Full Text] [Related]
8. Treosulfan-thiotepa-fludarabine-based conditioning regimen for allogeneic transplantation in patients with thalassemia major: a single-center experience from north India. Choudhary D; Sharma SK; Gupta N; Kharya G; Pavecha P; Handoo A; Setia R; Katewa S Biol Blood Marrow Transplant; 2013 Mar; 19(3):492-5. PubMed ID: 23160007 [TBL] [Abstract][Full Text] [Related]
9. [Effects and prognostic factors of HLA-matched sibling donor allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia]. Tong XZ; Li J; Tan EX; Zhang GC; Wu XY; Peng AH; Zheng D; Zou WY; Hong WD; Luo SK Zhonghua Zhong Liu Za Zhi; 2006 Jul; 28(7):545-8. PubMed ID: 17147125 [TBL] [Abstract][Full Text] [Related]
10. The Saudi experience in fludarabine-based conditioning regimens in patients with Fanconi anemia undergoing stem cell transplantation: excellent outcome in recipients of matched related stem cells but not in recipients of unrelated cord blood stem cells. Ayas M; Al-Seraihi A; El-Solh H; Al-Ahmari A; Khairy A; Aldali A; Markiz S; Siddiqui K; Al-Jefri A Biol Blood Marrow Transplant; 2012 Apr; 18(4):627-32. PubMed ID: 21871862 [TBL] [Abstract][Full Text] [Related]
11. Intravenous busulfan-cyclophosphamide as a preparative regimen before allogeneic hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia. Tang W; Wang L; Zhao WL; Chen YB; Shen ZX; Hu J Biol Blood Marrow Transplant; 2011 Oct; 17(10):1555-61. PubMed ID: 21549217 [TBL] [Abstract][Full Text] [Related]
12. Oral busulfan pharmacokinetics and engraftment in children with Hurler syndrome and other inherited metabolic storage diseases undergoing hematopoietic cell transplantation. Jacobson P; Park JJ; DeFor TE; Thrall M; Abel S; Krivit W; Peters C Bone Marrow Transplant; 2001 Apr; 27(8):855-61. PubMed ID: 11477444 [TBL] [Abstract][Full Text] [Related]
14. Alternative donor transplants for patients with advanced hematologic malignancies, conditioned with thiotepa, cyclophosphamide and antithymocyte globulin. Lamparelli T; van Lint MT; Gualandi F; Raiola AM; Barbanti M; Sacchi N; Ficai G; Ghinatti C; Bregante S; Berisso G; Dominietto A; Di Grazia C; Bruno B; Sessarego M; Casarino L; Verdiani S; Bacigalupo A Bone Marrow Transplant; 2000 Dec; 26(12):1305-11. PubMed ID: 11223970 [TBL] [Abstract][Full Text] [Related]
15. Bone marrow transplantation for Fanconi anemia using fludarabine-based conditioning. Stepensky P; Shapira MY; Balashov D; Trakhtman P; Skorobogatova E; Rheingold L; Brooks R; Revel-Vilk S; Weintraub M; Stein J; Maschan A; Or R; Resnick IB Biol Blood Marrow Transplant; 2011 Sep; 17(9):1282-8. PubMed ID: 21220033 [TBL] [Abstract][Full Text] [Related]
16. Risk adopted allogeneic hematopoietic stem cell transplantation using a reduced intensity regimen for children with thalassemia major. Hussein AA; Al-Zaben A; Ghatasheh L; Natsheh A; Hammada T; Abdel-Rahman F; Abu-Jazar H; Sharma S; Najjar R; Frangoul H Pediatr Blood Cancer; 2013 Aug; 60(8):1345-9. PubMed ID: 23424175 [TBL] [Abstract][Full Text] [Related]
17. Hematopoietic stem cell transplantation for Wiskott-Aldrich syndrome: an EBMT Inborn Errors Working Party analysis. Albert MH; Slatter MA; Gennery AR; Güngör T; Bakunina K; Markovitch B; Hazelaar S; Sirait T; Courteille V; Aiuti A; Aleinikova OV; Balashov D; Bernardo ME; Bodova I; Bruno B; Cavazzana M; Chiesa R; Fischer A; Hauck F; Ifversen M; Kałwak K; Klein C; Kulagin A; Kupesiz A; Kuskonmaz B; Lindemans CA; Locatelli F; Lum SH; Maschan A; Meisel R; Moshous D; Porta F; Sauer MG; Sedlacek P; Schulz A; Suarez F; Vallée TC; Winiarski JH; Zecca M; Neven B; Veys P; Lankester AC Blood; 2022 Mar; 139(13):2066-2079. PubMed ID: 35100336 [TBL] [Abstract][Full Text] [Related]
18. A Conditioning Regimen with Plerixafor Is Safe and Improves the Outcome of TCRαβ Balashov D; Laberko A; Shcherbina A; Trakhtman P; Abramov D; Gutovskaya E; Kozlovskaya S; Shelikhova L; Novichkova G; Maschan M; Rumiantsev A; Maschan A Biol Blood Marrow Transplant; 2018 Jul; 24(7):1432-1440. PubMed ID: 29550630 [TBL] [Abstract][Full Text] [Related]
19. The outcome of allogeneic hematopoietic stem cell transplants without total body irradiation in pediatric patients with acute lymphoblastic leukemia: single centre experience. Hamidieh A; Kargar M; Jahani M; Alimoghaddam K; Bahar B; Mousavi SA; Iravani M; Jalali A; Jalili M; Ghavamzadeh A J Pediatr Hematol Oncol; 2012 Mar; 34(2):101-7. PubMed ID: 22367385 [TBL] [Abstract][Full Text] [Related]
20. Comparative outcome of hematopoietic stem cell transplantation for pediatric acute lymphoblastic leukemia following cyclophosphamide and total body irradiation or VP16 and total body irradiation conditioning regimens. Gassas A; Sung L; Saunders EF; Doyle JJ Bone Marrow Transplant; 2006 Dec; 38(11):739-43. PubMed ID: 17013424 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]